Ksl-w(Ksl-w) - 在研适应症：牙龈炎_专利_临床

概要

基本信息

药物类型

合成多肽

别名-

靶点-

作用机制-

治疗领域

感染口颌疾病

在研适应症

牙龈炎

非在研适应症-

原研机构

United States Army Medical Research and Materiel Command

在研机构

United States Army Medical Research and Materiel Command

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Ksl-w 相关的临床试验

NCT02864901 / Completed临床2期IIT

A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population

This study is a Phase 2 two-armed placebo-controlled, double-blind, randomized (1:1), multiple dose, single center study to evaluate the safety and proof of concept in a chewing gum formulation 3 times per day over 4 treatment days.

开始日期2016-10-01

申办/合作机构

U S Army Medical Research & Development Command

NCT01877421 / Completed临床1/2期IIT

A Double-Blind, Randomized, Controlled, Dose Escalation Clinical Trial of an Antiplaque Chewing Gum - Phase 1 Safety and Tolerability and Phase 2a Safety, Tolerability, and Proof of Concept in a Gingivitis Population

This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.

开始日期2014-02-25

申办/合作机构

U S Army Medical Research & Development Command

100 项与 Ksl-w 相关的临床结果

登录后查看更多信息

100 项与 Ksl-w 相关的转化医学

登录后查看更多信息

100 项与 Ksl-w 相关的专利（医药）

登录后查看更多信息

40

项与 Ksl-w 相关的文献（医药）

2022-10-01·Drug Delivery and Translational Research3区 · 医学

Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice

3区 · 医学

Article

作者: Kumar, Vinod ; Cui, Cedric S ; Borges, Karin ; Xu, Weizhi ; Whittaker, Andrew K ; Smith, Maree T ; Maqbool, Faheem ; Woodruff, Trent M ; Han, Felicity Y ; Falconer, James R

Ketamine is used as an analgesic adjuvant in patients with chronic cancer-related pain. However, ketamine's short half-life requires frequent dose administration. Our aim was to develop a sustained release formulation of ketamine with high loading and to evaluate the in vivo pharmacokinetics and biodistribution in mice. Here, ketamine hydrochloride sustained-release lipid particles (KSL) were developed using the thin-film hydration method. The mean (± SD) encapsulation efficiency (EE) and drug loading (DL) of KSL were 65.6 (± 1.7)% and 72.4 (± 0.5)% respectively, and the mean (± SD) size of the lipid particles and the polydispersity index were 738 (± 137) nm and 0.44 (± 0.02) respectively. The release period of KSL in pH 7.4 medium was 100% complete within 8 h in vitro but a sustained-release profile was observed for more than 5 days after intravenous injection in mice. Importantly, the KSL formulation resulted in a 27-fold increase in terminal half-life, a threefold increase in systemic exposure (AUC_0-∞), and a threefold decrease in clearance compared with the corresponding pharmacokinetics for intravenous ketamine itself. Our findings demonstrate high encapsulation efficiency of ketamine in the sustained-release KSL formulation with prolonged release in mice after systemic dose administration despite 100% in vitro release within 8 h that requires future investigation.

2022-02-01·Food Research International1区 · 农林科学

Kefir modulates gut microbiota and reduces DMH-associated colorectal cancer via regulation of intestinal inflammation in adulthood offsprings programmed by neonatal overfeeding

1区 · 农林科学

Article

作者: Dutra Medeiros, Julliane ; Otavio do Amaral Corrêa, José ; Cristina Potente Dutra Luquetti, Sheila ; Barbosa Ferreira Machado, Alessandra ; Teodoro de Souza, Claudio ; Novaes Rocha, Vinícius ; Paula Boroni Moreira, Ana ; Guiomar de Almeida Brasiel, Poliana ; do Carmo Gouveia Peluzio, Maria

Obesity is associated with chronic inflammation, intestinal dysbiosis, and colorectal cancer risk. The anti-cancer effects of kefir are highlighted. Here, lactating Wistar rats were divided into: Normal litter (NL); Kefir normal litter (KNL); Small litter (SL); Kefir small litter (KSL). The NL and SL groups received 1 mL of water/day; KNL and KSL received kefir milk daily (10⁸ CFU/mL) during lactation. After weaning, the pups continued to receive the same treatments until 60 days. At 67 days old, colorectal carcinogenesis was induced through intraperitoneal injection of 1,2-dimethylhydrazine. At 240 days, visceral adipose tissue was higher in SL compared to NL, KNL, and KSL. Kefir intake was found to suppress the number of tumors in both KNL and KSL groups (-100% and -71.43%; p < 0.01, respectively). IL-1β, IL-6, TNF-α, and NO levels in the colon were higher in the NL and SL compared to the KNL and KSL. The gut microbiota in cecal samples of SL was enriched with Alloprevotella, Acinetobacter, and Bacteroides. In contrast, the cecal contents of KSL and KNL were higher Romboutsia. Thus, neonatal overfeeding leads to greater adiposity, inflammation and number of colon tumors in adulthood. Early-life nutrition based on kefir reverted these alterations.

2021-01-01·Journal of Natural Medicines4区 · 医学

Structure and anticancer activity of a new lectin from the cultivated red alga, Kappaphycus striatus

4区 · 医学

Article

作者: Trinh, Phan Thi Hoai ; Hung, Le Dinh

The red alga Kappaphycus striatus is economically important food species and extensively cultivated throughout most tropical parts of the world as a source of carrageenan. In this note, the primary structure of a new lectin KSL from this alga was elucidated by the rapid amplification method of complementary DNA (cDNA) ends, which consists of 267 amino acid residues distributed in four tandem-repeated domains of about 67 amino acids and sharing 43% of identity. The calculated molecular mass from the deduced sequence was consistent with that of natural KSL (27,826 Da) determined by electron spray ionization-mass spectrometry. The primary structure of KSL showed high similarity to those of the high mannose N-glycan specific lectins from marine red algae, ESA-2 from Eucheuma serra, EDA-2 from Eucheuma denticulatum, KSA-2 from Kappaphycus striatum, KAAs from Kappaphycus alvarezii and SfLs from Solieria filiformis, and from microorganisms, BOA from Burkholderia oklahomensis, MBHA from Myxococcus xanthus, OAA from Oscillatoria agardhii and PFL from Pseudomonas fluorescens. Furthermore, KSL showed anticancer effects against five carcinoma cell lines, HT29, Hela, MCF-7, SK-LU-1 and AGS, in a dose-dependent manner with the IC₅₀ values of 0.80-1.94 µM, whereas its inhibition activities on cancer cells were not detected in the presence of yeast mannan, an inhibitor against lectin KSL. The cultivated red alga K. striatus could also be a good source of functional lectin(s) for application as anticancer agents.

100 项与 Ksl-w 相关的药物交易

登录后查看更多信息